Haemato-oncology clinical trials
Clinical trials are an important part of improving treatment for patients.
Acute myeloid leukaemia (AML) trials
- Trial of dual aurora kinase, FLT3 inhibitor for adults with AML relapsed or refractory to conventional therapy
- Trial of MDM2 antagonist for patients with AML arising out of myeloproliferative disorders
- AML18 for untreated patients aged over 60 years with AML. Looking at liposomal daunorubicin and cytarabine versus standard daunorubicin and cytarabine and mylotarg for patients with de novo AML.
Acute lymphoblastic leukaemia (ALL) trials
- MEK inhibitor trial for relapsed/refractory acute lymphoblastic leukaemia with RAS-pathway mutations in adults